CAPR Stock Analysis: Buy, Sell, or Hold?
CAPR - Capricor Therapeutics Inc
$32.11
1.99 (6.61%)
▲
5d:
+7.21%
30d:
+25.92%
90d:
+11.26%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
CAPR is down 3.9% this week, but smart money is accumulating calls. Top strike: $40 2026-06-18 with 5,184 OI. Call ratio: 94% View Scanner →
Strength: 6.4/10
Get Alerted When CAPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CAPR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CAPR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CAPR is currently trading at $32.11, which is considered extended relative to its 30-day fair value range of $27.31 to $31.62. From a valuation perspective, the stock is trading at a discount (Forward PE: -84.5) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is approaching resistance at $32.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $53.90 (+67.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is approaching resistance at $32.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $53.90 (+67.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$27.31 -
$31.62
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 67.9% below Wall St target ($53.90)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$27.31 -
$31.62
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$27.50
Resistance Level
$32.45
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-84.50
Wall Street Target
$53.90
(+67.9%)
Revenue Growth (YoY)
-7.9%
PE vs Historical
-84.5 vs 133.6
CHEAP
Share & Embed Analysis
Last updated: April 06, 2026 9:41 AM ET
Data refreshes hourly during market hours. Next update: 10:41 AM
Data refreshes hourly during market hours. Next update: 10:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
Advanced CAPR Option Strategies
Professional options setups generated by AI based on today's CAPR price and gamma walls.
